Reported 1 day ago
LifeSci Capital has reaffirmed a Buy rating for Kura Oncology, Inc. (NASDAQ:KURA), setting a target price of $24. This decision underscores the promising potential of Kura's drug candidate KO-2806 for treating clear cell renal cell carcinoma (ccRCC), especially highlighted by expected presentations at ESMO 2025. Despite historical challenges faced by farnesyl transferase inhibitors, KO-2806's improved tolerability and response rate compared to current therapies indicate significant upside potential for investors as the market has overlooked this promising opportunity.
Source: YAHOO